News
Increasing Possibility of Success by Expanded Antibody Repertoires with Lambda Light Chain – Immunocan Launches New Mouse Strain of Fully Human Antibody Platform: ImmuMab® HKL Mouse
Release Date: 17 July 2024
Boston, July 17, 2024 - Immunocan announced the successful construction of new strain of fully human antibody platform: ImmuMab® HKL mouse. This new mouse was created by in-situ replacing the variable region of Immunoglobulin genes of mouse by its counterparts from human. With Lambda light chain genes humanized, ImmuMab® HKL mouse now contains approximately 3.2 Mb of human immunoglobulin variable region genes, making it the humanized mouse with the longest human immunoglobulin variable regions in the world.
Immunocan Launches Innovative Alpaca-derived Nanobody Discovery Platform: ImmuAlpaca® Mouse
Release Date: 01 June 2024
Boston, June 01, 2024 - Immunocan announces significant progress in the construction of its alpaca-derived nanobody discovery platform, ImmuAlpaca® mouse. The IGH-VDJ genes in the mouse genome have been successfully replaced by alpaca IGH-VDJ genes in-situ.
ImmuMab® mice generated Consistent and Stable Immune Responses as Wild-type Mice-Immunocan accelerating development of fully human antibodies
Release Date: 12 April 2023
In December 2022, Shanghai Immunocan Biotech Co., Ltd. launched ImmuMab® mouse, a fully human antibody discovery platform based on patented gene editing technology, and initiated mouse evaluation and application projects. Thus far, the four projects from different antigens have demonstrated stable immune responses as wild type mice, laying a solid foundation for further development of therapeutic antibodies.
Immunocan raised 50 million RMB in pre-A financing, led by Kingray Capital
Release Date: 16 August 2021
On August 16th, according to the report from the investment community, Shanghai Immunocan Biotech Co. (hereinafter referred to as “Immunocan”), a fully human antibody drug development company, has completed a Pre-A round of financing of RMB 50 million recently.
New Bispecific Antibody Platform - Immunocan Launches Common Light Chain Antibody Discovery Platform: ImmuMab Light® Mouse
Release Date: 24 June 2022
Boston, June 24, 2024 - Immunocan announces the completion of constructing its fully human common light chain antibody discovery platform, ImmuMab Light® mouse. This new platform will further enhance Immunocan's antibody discovery capabilities and make the development of fully human IgG-like bispecific antibodies easier.
Immunocan Provides Update on Business Operations, Highlighting Launch of New Gene-edited Mice Generating Fully Human Heavy-chain-only Antibodies and Advances in Partner Pipeline
Release Date: 21 December 2023
ImmuMab Heavy® mice are able to produce fully human antibodies, consisting solely of heavy chains, without the presence of light chains. These mice possess over 120 human immunoglobulin heavy-chain V genes at the mouse immunoglobulin gene loci, thanks to the parental strain ImmuMab® mice.
Immunocan pioneers Mb gene replacement technology to create a new fully human antibody mouse platform
Release Date: 03 December 2022
Along with the continuous development of antibody-based drug technology, monoclonal antibody drugs and innovative therapeutics based on monoclonal antibodies (bispecific antibody,